Literature DB >> 27912986

A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.

Robert C Read1, Peter Dull2, Xilian Bai3, Kate Nolan3, Jamie Findlow3, Rohit Bazaz4, Annett Kleinschmidt5, Maggie McCarthy2, Huajun Wang6, Daniela Toneatto7, Ray Borrow3.   

Abstract

BACKGROUND: University students have high rates of pharyngeal carriage of Neisseria meningitidis. Interruption of carriage acquisition is an important mechanism of vaccines for inducing herd protection. 4CMenB and MenACWY-CRM vaccines have been shown to be immunogenic against meningococcal serogroups B and ACWY respectively in younger age groups, and also to elicit a modest impact on meningococcal carriage in vaccinated students. However, vaccine responses in university students and the impact of serum bactericidal antibody (SBA) titers on meningococcal carriage are undetermined.
METHODS: Immunogenicity of two 4CMenB doses or one MenACWY-CRM dose was measured in university students at Months 2, 4, 6 and 12 post-first vaccination. Immunogenicity of one MenACWY-CRM dose in students with previous meningococcal serogroup C conjugate vaccination was also assessed. Immune responses were measured with an SBA assay using human complement (hSBA) against three reference strains for serogroup B and against one strain for each for serogroups C and Y. Correlations between hSBA titers and meningococcal carriage were analyzed.
RESULTS: All subjects demonstrated robust functional antibody responses to both vaccines at Month 2 and a high proportion maintained protective hSBA titers up to Month 12. At baseline, carriage of disease-associated serogroup B strains and serogroups C and Y were higher in subjects with already-protective hSBA titers. Post-vaccination, while both 4CMenB and MenACWY-CRM elicited robust immunogenicity in students, significant correlations between post-vaccination hSBA titers and carriage of disease-associated serogroups were not observed.
CONCLUSIONS: 4CMenB and MenACWY-CRM were both highly immunogenic. There was no correlation between carriage and post-vaccination hSBA titers.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Carriage; Immunogenicity; Meningococcal; Serogroup B; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27912986     DOI: 10.1016/j.vaccine.2016.11.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

2.  The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.

Authors:  Elizabeth Partridge; Eduardo Lujan; Serena Giuntini; David M Vu; Dan M Granoff
Journal:  Vaccine       Date:  2017-06-23       Impact factor: 3.641

Review 3.  Meningococcal disease and vaccination in college students.

Authors:  Sarah Schaffer DeRoo; Rachel G Torres; Linda Y Fu
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

4.  Cross-protection induced by VA-MENGOC-BC® vaccine.

Authors:  Rolando Felipe Ochoa-Azze
Journal:  Hum Vaccin Immunother       Date:  2018-02-26       Impact factor: 3.452

5.  Effect of Vaccine-Elicited Antibodies on Colonization of Neisseria meningitidis Serogroup B and C Strains in a Human Bronchial Epithelial Cell Culture Model.

Authors:  Vianca Vianzon; Beate Illek; Gregory R Moe
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

6.  Protocol for a controlled human infection with genetically modified Neisseria lactamica expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine.

Authors:  Diane Gbesemete; Jay Robert Laver; Hans de Graaf; Muktar Ibrahim; Andrew Vaughan; Saul Faust; Andrew Gorringe; Robert Charles Read
Journal:  BMJ Open       Date:  2019-05-01       Impact factor: 2.692

Review 7.  Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.

Authors:  Federico Martinón-Torres; Terry Nolan; Daniela Toneatto; Angelika Banzhoff
Journal:  Hum Vaccin Immunother       Date:  2019-07-09       Impact factor: 3.452

8.  Effect of complement Factor H on antibody repertoire and protection elicited by meningococcal capsular group B vaccines containing Factor H binding protein.

Authors:  Peter T Beernink
Journal:  Hum Vaccin Immunother       Date:  2019-10-22       Impact factor: 3.452

9.  Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.

Authors:  Andrew Stawasz; Liping Huang; Paige Kirby; David Bloom
Journal:  Front Public Health       Date:  2020-07-10

Review 10.  Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.

Authors:  Philippe De Wals
Journal:  Can J Infect Dis Med Microbiol       Date:  2019-11-25       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.